Why focus product discovery on existing customers?

Have you ever wondered why so many pharmaceutical brands spend millions chasing new clientele when their retention rates could be drastically improved? For global health-supplements companies, keeping current customers loyal reduces churn — a direct impact on lifetime value and predictable revenue. According to a 2024 IQVIA report, companies with retention rates above 85% in supplements saw a 12% higher EBITDA margin than peers. Product discovery isn’t just about innovation; it’s about ensuring that what you develop aligns so closely with ongoing customer needs that they stay engaged and don’t switch.

When executive project-management teams embed customer-retention as a priority in product discovery, you shift the focus from “What’s new?” to “What keeps our customers?” This mindset fundamentally changes project scoping, success metrics, and resource allocation — making discovery a strategic tool for competitive advantage.

1. Segment customer data by retention risk profiles

Do you really know which customers are most likely to churn before they leave? Advanced segmentation can identify retention risk clusters based on purchasing behavior, support interactions, and even physiological response data (like supplement efficacy feedback). For instance, a leading multinational health-supplement firm used machine learning to segment customers into five risk categories, reducing churn by 7% in 18 months after tailoring product discovery to the needs of the “high-risk but high-value” group.

The drawback? This requires integrating disparate data sources — sales, CRM, clinical trial outcomes — which can be complex for global organizations with legacy systems. Still, investing early in data infrastructure pays dividends in focused discovery.

2. Prioritize symptom-targeted discovery aligned with adherence drivers

What drives adherence in pharmaceutical supplements? Is it taste, dosing schedule, or perceived benefit? When product teams investigate which symptoms or outcomes customers prioritize, they can design offerings that naturally embed into daily routines, boosting loyalty. For example, a European company discovered that 64% of their mid-aged customers preferred supplements targeting joint mobility with once-a-day dosing — leading to a reformulation that increased month-over-month usage by 15%.

Here’s a caution: focusing only on symptom relief can overlook emotional or aspirational factors that sustain engagement longer term. Balance hard science with behavioral insights.

3. Use iterative pilot testing with customer cohorts

Can you afford to wait until final phases to learn if your product will retain customers? Iterative pilot programs, where new formulations or delivery methods are tested with select cohorts, accelerate learning about retention impact. In a 2023 case, one US-based health-supplements giant ran three rapid pilots with cohorts of 500 users each, refining the product based on real-time feedback via Zigpoll surveys and usage analytics. They reported a 4x increase in retention rates post-launch compared to traditional development.

The downside is complexity in managing multiple pilots simultaneously and ensuring regulatory compliance across regions — requiring tight cross-functional coordination.

4. Leverage ethnographic research for deep customer empathy

Do numbers tell the whole story about why customers stay or go? Ethnographic research, such as in-home user observations or immersive interviews, uncovers the nuanced context of supplement use. A Japanese pharma firm used ethnography to realize that social rituals around supplement intake (e.g., family health routines) were key engagement drivers, leading them to design products that supported group consumption — retention shot up 10% in six months.

Ethnography is time-consuming and costly, so it’s best deployed selectively for high-value segments or new market entries.

5. Integrate pharmacovigilance feedback loops into product discovery

How often does adverse event data feed directly back into your initial discovery phases? Pharmacovigilance isn’t just about compliance — it can signal potential product improvements or reformulations that enhance safety perceptions and reduce discontinuation. Pfizer’s supplement division, for instance, integrated real-world safety monitoring data into early-stage discovery, leading to a reformulated vitamin combo that saw a 20% drop in customer complaints and higher retention among sensitive populations.

Beware that this requires real-time data flows and regulatory alignment, which can slow down iteration cycles.

6. Embed cross-functional teams with retention KPIs

Is your product discovery siloed from marketing, sales, and customer success? Successful firms bring together multidisciplinary teams focused on retention outcomes, not just time-to-market or innovation counts. One pharma enterprise restructured its project management offices to include data scientists, behavior specialists, and customer success managers — retention KPIs like Net Promoter Score and renewal rate became board-level metrics tied to project bonuses.

This organizational shift isn’t trivial. It demands cultural change and executive sponsorship to avoid turf wars.

7. Deploy digital experience analytics alongside clinical efficacy

Can clinical trial success alone guarantee customer retention? Not anymore. Digital experience metrics — app engagement, refill frequency, customer support interactions — provide essential signals about ongoing satisfaction. A 2024 Forrester report showed 58% of pharma executives now measure digital engagement alongside efficacy data to predict churn risk.

One health-supplements team integrated app usage data into discovery, revealing that dosage reminders and educational content reduced churn by 9%. However, integrating these datasets often requires new IT investments and cross-departmental collaboration.

8. Use Zigpoll and other agile feedback tools for continuous insight

How often do you ask customers what they think during product development? Agile survey platforms like Zigpoll, SurveyMonkey, and Qualtrics allow rapid, targeted feedback loops that inform discovery adjustments focused on retention. A global supplement manufacturer implemented weekly Zigpoll insights during discovery, capturing shifting customer preferences and improving product-market fit, which lifted loyalty scores by 11% in six months.

The limitation? Survey fatigue and biased self-reporting require careful sampling and question design to maintain validity.

9. Benchmark retention metrics against competitive landscape

Do you know how your retention compares to peers? Benchmarking informs realistic goal-setting for discovery projects and highlights market differentiators. IQVIA’s 2024 Pharma Supplement Report provides retention norms by region, segment, and product type, helping executives set informed targets. One company improved retention by 5% simply by aligning discovery goals with top-quartile benchmarks, focusing on underdelivered supplement features.

But beware of over-reliance on benchmarks without considering unique customer segments or brand positioning nuances.

What to prioritize first?

Should you start with data-heavy segmentation, or jump into ethnographic research? For large global pharmaceutical corporations, investing in customer retention begins with integrating data streams to identify risk segments (#1) and embedding retention KPIs in cross-functional teams (#6). These steps create a foundation for agile pilots (#3) and digital analytics (#7) to accelerate learning.

Focus efforts where retention improvements yield the biggest ROI — often among mid-value customers with moderate churn risk, who represent untapped growth without the cost of acquiring new clients. Tools like Zigpoll offer fast, actionable feedback, so start small but scale feedback mechanisms continuously.

Ultimately, product discovery that centers on existing customer retention isn’t a side project—it’s a strategic imperative for sustained profitability in health-supplements pharmaceuticals. Would you rather chase new customers at high cost or deepen loyalty among those already invested? The answer should guide your discovery roadmap.